|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. e Equity
Price Risk
We are exposed to equity price risks primarily on our
available-for-sale investments, which include quoted investments
carried at a fair value of $2.7 million (2007:
$8.8 million). These investments are primarily in small
emerging pharmaceutical and biotechnology companies. A decrease
of 10% in equity prices would result in a decrease of
$0.3 million in the fair value of our available-for-sale
quoted investments. The decrease would be recognised directly in
equity unless it has been determined to be an impairment, in
which case, it would be recognised in the income statement. An
increase of 10% in equity prices would result in an increase of
$0.3 million in the fair value of our available-for-sale
quoted investments. The increase would be recognised directly in
equity.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. e Equity
Price Risk
We are exposed to equity price risks primarily on our
available-for-sale
investments, which include quoted investments carried at a fair
value of $8.8 million (2006: $11.2 million). These
investments are primarily in small emerging pharmaceutical and
biotechnology companies. A decrease of 10% in equity prices
would result in a decrease of $0.9 million in the fair
value of our
available-for-sale
quoted investments. The decrease would be recognised directly in
equity unless it has been determined to be an impairment, in
which case, it would be recognised in the income statement. An
increase of 10% in equity prices would result in an increase of
$0.9 million in the fair value of our
available-for-sale
quoted investments. The increase would be recognised directly in
equity.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Equity
Price Risk
We are exposed to equity price risks primarily on our equity
investments in publicly-quoted emerging pharmaceutical and
biotechnology companies. At December 31, 2007, these
investment securities had a fair value of $8.8 million and
a cost of $5.0 million. An adverse change in equity prices
could result in a material impact in the fair value of our
investments in equity securities.
Not applicable.
Table of Contents
This excerpt taken from the ELN 6-K filed Mar 30, 2007. d Equity
Price Risk
We are exposed to equity price risks primarily on our
available-for-sale
investments, which include quoted investments carried at a fair
value of $11.4 million (2005: $9.9 million). These
investments are primarily in emerging pharmaceutical and
biotechnology companies. An adverse change in equity prices
could result in a material impact in the fair value of our
available-for-sale
quoted investments.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Equity
Price Risk
We are exposed to equity price risks primarily on our investment
securities, which consist of equity investments in quoted
companies. At December 31, 2006, current investment
securities had a fair value of $11.2 million and had a cost
of $6.5 million. These investments are primarily in
emerging pharmaceutical and biotechnology companies. An adverse
change in equity prices could result in a material impact in the
fair value of our investments in equity securities.
Not applicable.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Equity Price Risk
We are exposed to equity price risks, primarily on our
available-for-sale investments, which include quoted investments
carried at a fair value of $9.9 million (2004: cost of
$28.1 million). These investments are primarily in emerging
pharmaceutical and biotechnology companies. An adverse change in
equity prices could result in a material impact in the fair
value of our available-for-sale quoted investments.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Equity
Price Risk
We are exposed to equity price risks primarily on our available
for sale securities, which consist of equity investments in
quoted companies. At December 31, 2005, current
available-for-sale
securities had a fair value of $10.0 million and had a cost
of $10.3 million. These investments are primarily in
emerging pharmaceutical and biotechnology companies. An adverse
change in equity prices could result in a material impact in the
fair value of our available for sale equity securities.
Not applicable.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
